4 Grants
2021
Development of a novel biochemical tool with tumor-selective theranostic anti-cancer potential
Motea, Edward A
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 5R21CA253645-02), $185,247USD, 2020-09-01 -- 2022-08-31
 
Tumor-selective use of PARP inhibitors against NQO1+ nonsmall cell lung cancer
Huang, Xiumei and Motea, Edward A
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 5R01CA221158-05), $362,731USD, 2017-06-07 -- 2022-11-30
2020
Development of a novel biochemical tool with tumor-selective theranostic anti-cancer potential
Motea, Edward A
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 1R21CA253645-01), $222,296USD, 2020-09-01 -- 2022-08-31
 
RPRD1B/Kub5/Hera, an RNA Pol II determinant that controls PARPi & IR sensitivity
Motea, Edward A
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 5R01CA210489-06), $360,281USD, 2016-07-05 -- 2021-06-30